Apparently clinical trials are not necessary for PNV to bring this to market.
Medtronic states, “Based on benchtop studies, not necessarily indicative of human clinical outcomes. Compared to a flat sheet mesh with the same level of suture fixation. Based on preclinical testing, not necessarily indicative of human clinical outcomes.” I think this may be because, “…while gradually resorbing into the body over time.”
It’s taken longer than expected to bring their hernia product to market, which is reflected in the current stock price. If the timeline mentioned in the Macquire presentation is accurate, we should be getting an update soon, and it seems like they have the manufacturing capacity.
Stock could easily increase 25% on this update alone, IMHO.
Medtronic has entered the market for resorbable mesh Ventral Hernia Repair, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.54 |
Change
0.110(4.53%) |
Mkt cap ! $1.753B | |||
| Open | High | Low | Value | Volume |
| $2.46 | $2.57 | $2.46 | $3.283M | 1.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5750 | $2.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.55 | 3040 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |